StockNews.AI
AVDL
StockNews.AI
19 days

Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7

1. Avadel Pharmaceuticals will host a Q2 financial results call on August 7. 2. LUMRYZ™ is the first FDA-approved oxybate for narcolepsy in patients 7 and older. 3. The webcast will be available for 90 days following the event.

Earnings
+2.34%Current Return
VS
-1.99%S&P 500
$10.707/31 08:09 AM EDTEvent Start
$10.9508/01 02:30 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

Positive financial results could spur investor confidence in AVDL post-call, similar to past Q2 announcements where stocks rose significantly.

How important is it?

Upcoming earnings call could influence stock performance, especially if performance highlights momentum for LUMRYZ™.

Why Short Term?

Expected immediate market reaction following financial results announcement; historical trends support short-term impacts.

Related Companies

PFESNYAVLR
July 31, 2025 08:00 ET  | Source: Avadel Pharmaceuticals plc DUBLIN, Ireland, July 31, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 7, 2025, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2025. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. About Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years and older with narcolepsy. For more information, please visit www.avadel.com. Investor Contact:Austin Murtagh Precision AQAustin.Murtagh@precisionAQ.com (212) 698-8696 Media Contact:Alyssa RamirezReal Chemistryaramirez@realchemistry.com 

Related News